2025Q4
| Insider | Role (last 12 mo) | Shares held | Filed at |
|---|---|---|---|
| Barchas Isaac | Director | 2,834,008 | Oct 12, 2023 |
| Rapp Michael | Director | 827,640 | Oct 1, 2020 |
| Siegall Clay B | CEO | 806,736 | Mar 26, 2025 |
| Wagenheim Philip | Director | 406,147 | Jan 17, 2023 |
| Prendergast Franklyn G | — | 137,725 | Oct 4, 2023 |
| Exec date | Filing date | Insider | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Dec 30, 2025 | Dec 30, 2025 | SIEGALL CLAY B | CEO | Buy | 72.5 | +4,729 | 0.72% | ✗ | $100K |
| Dec 22, 2025 | Dec 23, 2025 | Barchas Isaac | Director | Sell | 26.9 | -383,200 | -8.42% | ✓ | $8.3M |
| Dec 19, 2025 | Dec 22, 2025 | Higgins Jack | Chief Scientific Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Dec 19, 2025 | Dec 22, 2025 | SIEGALL CLAY B | CEO | Buy | 22.5 | -192,722 | -22.59% | ✗ | $149.1K |
| Dec 19, 2025 | Dec 22, 2025 | Tsai Philip | Chief Technical Officer | Buy | 95.0 | +10,000 | 30.03% | ✗ | $204.9K |
| Dec 18, 2025 | Dec 18, 2025 | SIEGALL CLAY B | CEO | Buy | 92.5 | +46,511 | 5.77% | ✗ | $1000K |
| Sep 10, 2025 | Sep 11, 2025 | Higgins Jack | Chief Scientific Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jul 29, 2025 | Jul 31, 2025 | Tsai Philip | Chief Technical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jul 29, 2025 | Jul 31, 2025 | Rosett Max | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jul 29, 2025 | Jul 31, 2025 | Lechleider Robert | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jul 29, 2025 | Jul 31, 2025 | Horn Kinney | CHIEF BUSINESS OFFICER | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jul 29, 2025 | Jul 31, 2025 | Higgins Jack | Chief Scientific Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jul 29, 2025 | Jul 31, 2025 | SIEGALL CLAY B | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jul 29, 2025 | Jul 31, 2025 | Stoneman Sandra G. | CHIEF LEGAL OFFICER & GC | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 10, 2025 | Jun 12, 2025 | Boylan James P | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 10, 2025 | Jun 12, 2025 | SCHAFER CAROL | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 10, 2025 | Jun 12, 2025 | WAGENHEIM PHILIP | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 10, 2025 | Jun 12, 2025 | Barchas Isaac | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 10, 2025 | Jun 12, 2025 | BIENAIME JEAN JACQUES | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 10, 2025 | Jun 12, 2025 | SWAIN SANDRA M | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 3, 2025 | Jun 3, 2025 | BIENAIME JEAN JACQUES | Director | Buy | 91.3 | +5,000 | 15.92% | ✗ | $46.9K |
| Mar 27, 2025 | Mar 28, 2025 | Higgins Jack | Chief Scientific Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 25, 2025 | Mar 26, 2025 | BIENAIME JEAN JACQUES | Director | Buy | 95.0 | +7,800 | 33.03% | ✗ | $60.7K |
| Mar 26, 2025 | Mar 26, 2025 | SIEGALL CLAY B | CEO | Buy | 97.5 | +137,100 | 20.47% | ✗ | $999.5K |
| Mar 24, 2025 | Mar 25, 2025 | BIENAIME JEAN JACQUES | Director | Buy | 95.0 | +7,000 | 42.13% | ✗ | $57.5K |
| Mar 24, 2025 | Mar 25, 2025 | Tsai Philip | Chief Technology Officer | Buy | 95.0 | +12,300 | 58.57% | ✗ | $103.6K |
| Jan 31, 2025 | Feb 3, 2025 | SIEGALL CLAY B | CEO | Buy | 100.0 | +150,000 | 28.87% | ✗ | $1.2M |
| Nov 21, 2024 | Nov 25, 2024 | SIEGALL CLAY B | CEO | Buy | 97.5 | +100,000 | 23.83% | ✗ | $962.2K |
| Nov 21, 2024 | Nov 25, 2024 | Lechleider Robert | Chief Medical Officer | Buy | 95.0 | +15,805 | 100.00% | ✗ | $149.8K |
| Nov 21, 2024 | Nov 25, 2024 | Tsai Philip | Chief Technology Officer | Buy | 95.0 | +21,000 | 100.00% | ✗ | $198K |
| Sep 19, 2024 | Sep 20, 2024 | Rosett Max | CFO | Sell | 22.5 | -14,380 | -23.25% | ✗ | $230.2K |
| Aug 16, 2024 | Aug 19, 2024 | BIENAIME JEAN JACQUES | Director | Buy | 95.0 | +7,000 | 72.80% | ✗ | $97.6K |
| Aug 15, 2024 | Aug 19, 2024 | Higgins Jack | Chief Scientific Officer | Sell | 26.3 | -5,995 | -30.71% | ✗ | $49.1K |
| Aug 9, 2024 | Aug 13, 2024 | SIEGALL CLAY B | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 9, 2024 | Aug 13, 2024 | Stoneman Sandra G. | CHIEF LEGAL OFFICER & GC | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 9, 2024 | Aug 13, 2024 | Horn Kinney | CHIEF BUSINESS OFFICER | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 9, 2024 | Aug 13, 2024 | Turner Bruce | Chief Strategy Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 9, 2024 | Aug 13, 2024 | Rosett Max | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 9, 2024 | Aug 13, 2024 | Lechleider Robert | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 9, 2024 | Aug 13, 2024 | Higgins Jack | Chief Scientific Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 17, 2024 | Jun 18, 2024 | Tsai Philip | Chief Technology Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 18, 2024 | Tsai Philip | Chief Technology Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jun 13, 2024 | Jun 18, 2024 | Boylan James P | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 13, 2024 | Jun 18, 2024 | SCHAFER CAROL | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 13, 2024 | Jun 18, 2024 | SWAIN SANDRA M | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 13, 2024 | Jun 18, 2024 | WAGENHEIM PHILIP | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 13, 2024 | Jun 18, 2024 | BIENAIME JEAN JACQUES | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 13, 2024 | Jun 18, 2024 | Barchas Isaac | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 21, 2024 | May 22, 2024 | BIENAIME JEAN JACQUES | Director | Buy | 91.3 | +2,000 | 26.26% | ✗ | $27.1K |
| May 20, 2024 | May 21, 2024 | SIEGALL CLAY B | CEO | Buy | 100.0 | +100,000 | 31.29% | ✗ | $1.4M |
| May 16, 2024 | May 17, 2024 | Rosett Max | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 25, 2024 | Apr 29, 2024 | SWAIN SANDRA M | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 29, 2024 | SWAIN SANDRA M | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 20, 2024 | Feb 21, 2024 | Horn Kinney | CHIEF BUSINESS OFFICER | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 21, 2024 | Horn Kinney | CHIEF BUSINESS OFFICER | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jan 31, 2024 | Jan 31, 2024 | Rosett Max | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 31, 2024 | Jan 31, 2024 | Stoneman Sandra G. | CHIEF LEGAL OFFICER & GC | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 4, 2024 | Lapetina Bob | PAO and VP Finance & Corporate | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jan 2, 2024 | Jan 4, 2024 | SCHAFER CAROL | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 4, 2024 | SCHAFER CAROL | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Dec 13, 2023 | Dec 15, 2023 | Roberts Phil Noland | Chief Technology Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Dec 15, 2023 | Roberts Phil Noland | Chief Technology Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Dec 1, 2023 | Dec 5, 2023 | Higgins Jack | Chief Scientific Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Nov 7, 2023 | Nov 9, 2023 | BIENAIME JEAN JACQUES | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Nov 9, 2023 | BIENAIME JEAN JACQUES | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Oct 27, 2023 | Oct 31, 2023 | Barchas Isaac | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Oct 27, 2023 | Oct 31, 2023 | Boylan James P | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Oct 27, 2023 | Oct 31, 2023 | Lechleider Robert | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Oct 20, 2023 | Lechleider Robert | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Oct 12, 2023 | Barchas Isaac | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Oct 12, 2023 | Rosett Max | SVP Operations | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Oct 12, 2023 | Higgins Jack | Chief Scientific Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Oct 12, 2023 | Boylan James P | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Oct 2, 2023 | Oct 4, 2023 | SIEGALL CLAY B | CEO | Buy | 97.5 | +169,204 | 112.48% | ✗ | $1000K |
| Oct 4, 2023 | SIEGALL CLAY B | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Oct 2, 2023 | Oct 4, 2023 | Turner Bruce | Chief Strategy Officer | Buy | 95.0 | +42,300 | 100.00% | ✗ | $250K |
| Oct 4, 2023 | Turner Bruce | Chief Strategy Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Oct 2, 2023 | Oct 4, 2023 | PRENDERGAST FRANKLYN G | Director | Neutral | 90.0 | +60,840 | 100.00% | ✗ | - |
| Oct 2, 2023 | Oct 3, 2023 | RAPP MICHAEL | Director | Neutral | 90.0 | +253,806 | 24.73% | ✗ | - |
| Jun 8, 2023 | Jun 12, 2023 | RAPP MICHAEL | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 8, 2023 | Jun 12, 2023 | Stoneman Sandra G. | General Counsel and CLO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 8, 2023 | Jun 12, 2023 | Roche Corleen M. | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 8, 2023 | Jun 12, 2023 | ROBINSON MATTHEW K | Chief Technology Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 8, 2023 | Jun 12, 2023 | Sarma Purnanand D | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 8, 2023 | Jun 12, 2023 | Lefenfeld Michael | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 8, 2023 | Jun 12, 2023 | LAMATTINA JOHN L | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 8, 2023 | Jun 12, 2023 | BARON RICHARD A | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 8, 2023 | Jun 12, 2023 | PRENDERGAST FRANKLYN G | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 8, 2023 | Jun 12, 2023 | WAGENHEIM PHILIP | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 8, 2023 | Jun 12, 2023 | Giesing Dennis H | Chief Development Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 15, 2023 | Jan 17, 2023 | WAGENHEIM PHILIP | Director | Neutral | 77.5 | +8,750 | 2.20% | ✗ | - |
| Jan 15, 2023 | Jan 17, 2023 | LAMATTINA JOHN L | Director | Neutral | 90.0 | +15,125 | 29.18% | ✗ | - |
| Jan 15, 2023 | Jan 17, 2023 | Lefenfeld Michael | Director | Neutral | 90.0 | +13,875 | 51.63% | ✗ | - |
| Jan 15, 2023 | Jan 17, 2023 | RAPP MICHAEL | Director | Neutral | 77.5 | +17,500 | 1.74% | ✗ | - |
| Jun 16, 2022 | Jun 21, 2022 | Stoneman Sandra G. | General Counsel and CLO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 16, 2022 | Jun 21, 2022 | Sarma Purnanand D | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 16, 2022 | Jun 21, 2022 | Roche Corleen M. | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 16, 2022 | Jun 21, 2022 | ROBINSON MATTHEW K | Chief Technology Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 16, 2022 | Jun 21, 2022 | Giesing Dennis H | Chief Development Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 16, 2022 | Jun 21, 2022 | WAGENHEIM PHILIP | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |